Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Forma, Cancer Research Technology launch two spinouts

    Forma Therapeutics Inc. (Watertown, Mass.) and Cancer Research Technology Ltd. (London, U.K.), the commercial arm of the not-for-profit Cancer Research U.K., launched two virtual companies to develop compounds against …

    Published on 3/23/2015
  • COMPANY NEWS: ImmunoGen surges on ADC deal with Takeda

    ImmunoGen Inc. (NASDAQ:IMGN) gained $1.25 (17%) to $8.69 on Monday on news that Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) licensed exclusive rights to the biotech's antibody-drug conjugate (ADC) technology to develop …

    Published on 3/23/2015
  • COMPANY NEWS: Management tracks

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) appointed Timothy Wright as EVP of business development, strategy and innovation, effective April 13. Wright was director of the Drug Discovery and Development Institute …

    Published on 3/23/2015
  • COMPANY NEWS: Pfizer, Lilly to resume Phase III tanezumab program

    Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) said they would resume Phase III development of tanezumab to treat chronic pain after FDA lifted a partial clinical hold on the compound. In December 2012, FDA …

    Published on 3/23/2015
  • COMPANY NEWS: Zai gains China rights to BMS's brivanib

    Bristol-Myers Squibb Co.(NYSE:BMY) granted Zai Laboratory Inc. (Shanghai, China) exclusive rights in China, including Hong Kong and Macau, to oral brivanib to treat oncology indications including hepatocellular …

    Published on 3/23/2015
  • COMPANY NEWS: AstraZeneca, Daiichi in Movantik commercialization deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) partnered to co-commercialize AZ's Movantik naloxegol in the U.S. The peripheral mu opioid receptor (OPRM1; MOR) antagonist is approved to …

    Published on 3/20/2015
  • COMPANY NEWS: Lilly to commercialize biologics discovered in China

    Innovent Biologics Inc. (Suzhou, China) has signed a co-development deal with Eli Lilly and Co. (NYSE:LLY) for biologics discovered in China. Innovent will receive $56 million up front and is eligible for more than $400…

    Published on 3/20/2015
  • COMPANY NEWS: Sanofi, Evotec enter multi-part collaboration

    Evotec AG (Xetra:EVT) gained EUR 0.27 to EUR 3.99 on Friday after it entered a multifaceted collaboration with Sanofi (Euronext:SAN; NYSE:SNY), including a five-year oncology research deal.The companies intend to …

    Published on 3/20/2015
  • COMPANY NEWS: Amicus speeds Amigal submission timeline

    Amicus Therapeutics Inc. (NASDAQ:FOLD) rose $3.11 (33%) to $12.46 on Thursday after the company said it will submit regulatory applications in the U.S. and Europe this year for Amigal migalastat to treat Fabry's disease…

    Published on 3/19/2015
  • COMPANY NEWS: Court sides with Sandoz in Amgen biosimilar case

    The U.S. District Court for the Northern District of California denied motions made by Amgen Inc. (NASDAQ:AMGN) against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that would have delayed sales of Zarxio …

    Published on 3/19/2015
  • COMPANY NEWS: FDA panel backs Breo Ellipta for adults, not children

    FDA's Pulmonary-Allergy Drugs Advisory and Drug Safety and Risk Management Advisory committees voted 16-4 to recommend approval of Breo Ellipta fluticasone furoate/vilanterol from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)…

    Published on 3/19/2015
  • COMPANY NEWS: J&J buys single-asset anticoagulant company XO1

    The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) acquired XO1 Ltd. (Cambridge, U.K.), a single-asset cardiovascular company developing preclinical anticoagulant ichorcumab. J&J spokesperson Ellen …

    Published on 3/19/2015
  • COMPANY NEWS: Lilly licenses Hanmi's Btk inhibitor

    Eli Lilly and Co. (NYSE:LLY) obtained exclusive, worldwide rights outside of certain Asian territories to HM71224, an oral Bruton's tyrosine kinase (Btk) inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). The…

    Published on 3/19/2015
  • COMPANY NEWS: Management tracks

    Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc., which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).Ophthalmic play …

    Published on 3/19/2015
  • COMPANY NEWS: Management tracks

    Agilent Technologies Inc. (NYSE:A) promoted Mike McMullen from COO to CEO; he will retain his role as president. He succeeds William Sullivan, who will be a company advisor until his retirement on Oct. 31. Trovagene Inc…

    Published on 3/18/2015
  • COMPANY NEWS: FDA reviewers focus on safety of Breo Ellipta

    FDA will ask its Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees to vote on whether to recommend a large pre- or post-approval safety trial to evaluate serious asthma outcomes for Breo …

    Published on 3/17/2015
  • COMPANY NEWS: Galapagos, J&J terminate inflammation deal

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) and the Janssen Pharmaceutica NV unit of Johnson & Johnson (NYSE:JNJ) terminated a 2007 deal to develop small molecules for inflammation. Galapagos will regain all rights to …

    Published on 3/17/2015
  • COMPANY NEWS: Management tracks

    Molecular Partners AG (SIX:MOLN) named Andreas Harstrick CMO, effective May 1. Harstrick was SVP of medical science at the ImClone Systems Inc. subsidiary of Eli Lilly and Co. (NYSE:LLY); he served on Lilly's oncology …

    Published on 3/17/2015
  • COMPANY NEWS: Management tracks

    Oral therapies developer Chiasma Inc. (Jerusalem, Israel) named Mark Leuchtenberger president and CEO. Leuchtenberger was president and CEO of Acusphere Inc. (Pink:ACUS). Leuchtenberger succeeds Roni Mamluk, whom …

    Published on 3/16/2015
  • COMPANY NEWS: Merck expects third FDA rejection for sugammadex

    FDA canceled Wednesday's meeting of its Anesthetic and Analgesic Drug Products Advisory Committee to discuss sugammadex (MK-8616) from Merck & Co. Inc. (NYSE:MRK). The company said it expects to receive a complete …

    Published on 3/16/2015
  • COMPANY NEWS: Valeant raises Salix bid, Endo retreats

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) raised its bid to acquire Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to $173 per share, or $11.4 billion in cash, while competing bidder Endo International …

    Published on 3/16/2015
  • COMPANY NEWS: Boehringer eyeing NASH space with Pharmaxis option

    Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire worldwide rights to PXS4728A. According to Pharmaxis, Boehringer is interested in developing the…

    Published on 3/13/2015
  • COMPANY NEWS: District court hears Amgen, Sandoz biosimilars case

    The U.S. District Court for the Northern District of California on Friday accepted motions in the biosimilars dispute between Amgen Inc. (NASDAQ:AMGN) and the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that could …

    Published on 3/13/2015
  • COMPANY NEWS: Samsung Bioepis submits MAA for Remicade biosimilar

    Samsung Bioepis Co. Ltd., a JV between Samsung Group (Seoul, South Korea) and Biogen Idec Inc. (NASDAQ:BIIB), submitted an MAA to EMA for SB2, a biosimilar of autoimmune drug Remicade infliximab from Merck & Co. Inc. (…

    Published on 3/13/2015
  • COMPANY NEWS: SEC: Gilead, Vertex can't block shareholder vote on pricing risk

    Gilead Sciences Inc. (NASDAQ:GILD) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) have been told they must allow shareholders to vote on proposals by the UAW Retiree Medical Benefits Trust asking the companies to …

    Published on 3/13/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993